By SPC News Staff
The FDA expanded the use of the antiviral drug remdesivir (Veklury, Gilead) to outpatient adults and children with mild to moderate COVID-19 who are at high risk for hospitalization.
Previously, the use of remdesivir was limited to patients requiring hospitalization.
The FDA expanded the approved indication for remdesivir to include its use in adults and children (≥12 years of age who weigh ≥40 kg) with a positive direct SARS-CoV-2 viral test.
The agency also